

7 June 2024

NOT FOR DISTRIBUTION OR RELEASE TO U.S. WIRE SERVICES IN THE UNITED STATES

Dear Shareholder

Immutep Limited Entitlement Offer – Notification to ineligible shareholders

On Monday, 3 June 2024, Immutep Limited ACN 009 237 889 (ASX: IMM) (**Immutep** or **Company**) announced a fully underwritten placement to institutional investors of new fully paid ordinary shares in Immutep (**New Shares**) (**Placement**) and an accelerated non-renounceable pro rata entitlement offer to eligible shareholders to subscribe for 1 New Share for every 16 existing fully paid ordinary shares in Immutep (**Shares**) held as at 7.00pm (Sydney, Australia time) on the record date (being Wednesday, 5 June 2024) (**Record Date**) (**Entitlement**) at an issue price of A\$0.38 per New Share (**Entitlement Offer** and, together with the Placement, the **Offer**).

The Entitlement Offer comprises an institutional component (**Institutional Entitlement Offer**) and an offer to Eligible Retail Shareholders (as defined below) to participate on the same terms (**Retail Entitlement Offer**).

On Wednesday, 5 June 2024, the Company announced that it had successfully raised approximately A\$17.6 million under the Institutional Entitlement Offer and approximately A\$72.0 million under the Placement. The Retail Entitlement Offer is non-renounceable, and Entitlements that are not taken up by eligible shareholders, together with the Entitlements of ineligible shareholders, will lapse.

The Entitlement Offer is being made by Immutep in accordance with section 708AA of the *Corporations Act 2001* (**Corporations Act**) as modified by the Australian Securities and Investments Commission Corporations (Non-Traditional Rights Issues) Instrument 2016/84. The Institutional Entitlement Offer and the Retail Entitlement Offer together will raise approximately A\$28.2 million.

Documents relating to the Retail Entitlement Offer were lodged with the Australian Securities Exchange (**ASX**) today and made available to Eligible Retail Shareholders.

This letter has been sent to you to inform you about the Retail Entitlement Offer and to explain why you will not be able to subscribe for New Shares under the Retail Entitlement Offer. This letter is not an offer to issue New Shares to you, nor an invitation for you to apply for New Shares. **You are not required to do anything in response to this letter but there may be financial implications for you as a result of the Entitlement Offer that you should be aware of.**

Details of the Retail Entitlement Offer

The Retail Entitlement Offer is being made to Eligible Retail Shareholders on the basis of 1 New Share for every 16 existing Shares held at 7.00pm (Sydney, Australia time) on the Record Date, being Wednesday, 5 June 2024.

Eligibility criteria

Immutep has determined, pursuant to section 9A(3) of the Corporations Act and ASX Listing Rule 7.7.1(a), that it would be unreasonable to make offers to Immutep shareholders in all countries in connection with the Retail Entitlement Offer. Accordingly, in compliance with section 9A(3) of the Corporations Act and ASX Listing Rule 7.7.1(b), Immutep wishes to inform you that it will not be extending the Retail Entitlement Offer to you and you will not be able to subscribe for New Shares under the Retail Entitlement Offer.

Shareholders who are eligible to participate in the Retail Entitlement Offer (**Eligible Retail Shareholders**) are those shareholders of Immutep who:

- (a) are registered as a holder of Shares as at the Record Date, being 7.00pm (Sydney, Australia time) on Wednesday, 5 June 2024;
- (b) have a registered address on Immunetep's share register that is in Australia or New Zealand (each, an **Offer Jurisdiction**);
- (c) are not in the United States and are not acting for the account or benefit of a person in the United States (to the extent such shareholders hold securities in Immunetep for the account or benefit of such persons in the United States);
- (d) other than those holders of Shares who have an address in an Offer Jurisdiction on Immunetep's share register, are eligible under all applicable laws to receive an offer under the Entitlement Offer without a prospectus, disclosure document, product disclosure statement or any lodgement, filing, registration or qualification; and
- (e) were not invited to participate, (other than as nominee in respect of other underlying holdings) in the Institutional Entitlement Offer and were not treated as an ineligible institutional shareholder under the Institutional Entitlement Offer.

Shareholders who are not Eligible Retail Shareholders are ineligible retail shareholders and are consequently unable to participate in the Retail Entitlement Offer. Immunetep may (at its absolute discretion) extend the Retail Entitlement Offer to certain institutional shareholders in foreign jurisdictions who did not participate in the Institutional Entitlement Offer (subject to compliance with applicable laws).

Non-renounceable offer

As the Retail Entitlement Offer is non-renounceable, entitlements in respect of the New Shares you would have been entitled to if you were an Eligible Retail Shareholder will lapse and you will not receive any payment or value for your entitlements in respect of any New Shares that would have been offered to you if you had been eligible. New Shares equivalent to the number of New Shares you would have been entitled to if you were an Eligible Retail Shareholder may be allocated to other Eligible Retail Shareholders who subscribe for New Shares in excess of their entitlement under the Retail Entitlement Offer.

Further information

If you have any questions in relation to any of the above matters, please contact the Entitlement Offer Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) from 8.30am to 5.00pm (Sydney, Australia time) Monday to Friday.

On behalf of the board of directors and management of Immunetep, thank you for your continued interest in Immunetep.

Yours faithfully,



Deanne Miller
COO, General Counsel & Company Secretary
Immunetep Limited

This letter is not a prospectus or offering document under Australian law or under any other law. No action has been or will be taken to register, qualify or otherwise permit a public offering of the New Shares in any jurisdiction outside Australia, New Zealand. This letter is for information purposes only and does not constitute or form part of an offer, invitation, solicitation, advice or recommendation with respect to the issue, purchase or sale of any New Shares in Immutep.

This notice does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares have not been and will not be registered under the U.S. Securities Act of 1933 (the **Securities Act**) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States unless they are registered under the Securities Act or unless they are offered or sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. The New Shares to be offered and sold in the Retail Entitlement Offer may only be offered and sold outside the United States in “offshore transactions” (as defined in Regulation S under the Securities Act) in reliance on Regulation S under the Securities Act.

The provision of this document is not, and should not be considered as, financial product advice. The information in this document is general information only, and does not take into account your individual objectives, taxation position, financial situation or needs. If you are unsure of your position, please contact your accountant, tax advisor, stockbroker, solicitor or other professional advisor.